Ulcerative Colitis (UC) Market in China 2023

According to the latest estimates, the ulcerative colitis in China market size is expected to increase from USD 857.8 million in 2022 to USD 2,061.0 million by 2029, garnering a CA

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the colon and rectum, which can lead to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The exact cause of ulcerative colitis is unknown, but it is thought to be related to an abnormal immune response in which the body's immune system attacks the cells of the digestive tract. The condition may also be influenced by genetic and environmental factors. There are several treatment options available to manage the symptoms and complications of ulcerative colitis, including medications to reduce inflammation and suppress the immune system, dietary changes, and surgery to remove the affected portion of the colon or rectum in severe cases. According to the latest estimates, the ulcerative colitis in China market size is expected to increase from USD 857.8 million in 2022 to USD 2,061.0 million by 2029, garnering a CAGR of 13.09% over the evaluated period. This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and product. The China market data on ulcerative colitis can be segmented by type: mild ulcerative colitis, moderate to severe ulcerative colitis. Ulcerative colitis market is further segmented by product: infliximab, mesalazine, sulfasalazine (SSZ), others.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

As of 2022, the major players in the China ulcerative colitis market were Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd. The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors. Why buy this report? ? Get a detailed picture of the China Ulcerative Colitis Market ? Identify segments/areas to invest in over the forecast period in the China Ulcerative Colitis Market ? Understand the competitive environment, the market’s leading players ? The market estimate for ease of analysis across scenarios in Excel format. ? Strategy consulting and research support for three months. ? Print authentication provided for the single-user license.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Table of Contents

  • Part 1. Summary
  • Part 2. Introduction
  • Study period
  • Geographical scope
  • Market segmentation
  • Part 3. Ulcerative colitis market overview
  • Part 4. Market breakdown by type
  • Mild ulcerative colitis
  • Moderate to severe ulcerative colitis
  • Part 5. Market breakdown by product
  • Infliximab
  • Mesalazine
  • Sulfasalazine (SSZ)
  • Others
  • Part 6. Key companies
  • Losan Pharma GmbH
  • Ferring Holding SA
  • Guangdong Qiangji Pharmaceutical Co., Ltd.
  • Janssen Pharmaceuticals, Inc.
  • Shanghai Sine Tianping Pharmaceutical Co., Ltd.
  • Part 7. Methodology


Ulcerative Colitis (UC) Market in China 2023

Contact usWe are friendly and approachable, give us a call.